<DOC>
	<DOCNO>NCT02263313</DOCNO>
	<brief_summary>In study , safety efficacy COMBO TM stent beyond 36 month assess , particular occurrence late stent thrombosis late loss catch-up ( restenosis ) .</brief_summary>
	<brief_title>EGO-COMBO Clinical End-point Extension Study Beyond 36 Months</brief_title>
	<detailed_description>The Genous Stent ( EPC Capture R-stent , OrbusNeich Medical Inc. , Fort Lauderdale , FL ) commercially available use extensively standard coronary intervention treatment 200 patient critical coronary stenosis Queen Mary Hospital . The COMBO Stent ( OrbusNeich Medical Inc. , Fort Lauderdale , FL ) improve version Genous Stent widely available clinical use Hong Kong hospital . To date , 300 patient Queen Mary Hospital receive COMBO stent treatment coronary artery disease , remain stable clinically . The Genous Stent bio-engineered 316L stainless steel coronary stent biocompatible coat specific CD34 antibody inner surface . CD34 surface antigen present circulate endothelial progenitor cell ( EPC ) . It bond CD34 antibody , result capture EPC onto stent surface differentiation endothelial layer . Animal model demonstrate functional endothelial layer could form soon 24 48 hour Genous stent implantation ( 1 ) . The HEALING-FIM registry show Genous stent clinically safe effective treatment coronary stenosis ( 2 ) . Recent report confirm efficacy patient acute coronary syndrome require urgent revascularization ( 3,4 ) . The COMBO Stent improve version Genous Stent . The stent delivers drug call sirolimus treat coronary blood vessel . This stent also incorporate CD34 antibody coating design promote heal treated coronary artery catch endothelial progenitor cell circulate blood pas stent . These cell pro-healing help blood vessel wall heal stent quickly restore normal tissue function stented area . The combination two technology new Combo stent expect produce even well clinical result , publish REMEDEE Study . Pre-clinical animal study already show Combo Stent promote endothelialization reduce neointima formation , assess optical coherence tomography ( OCT ) histopathology ( 5 ) . However , beneficial endothelial coverage assess OCT never document human subject , address previous study protocol : EGO Study ( IRB : UW 10-256 ) , EGO-COMBO Pilot Study ( UW 10-342 ) EGO-COMBO angiographic extension study ( UW 12-472 ) . Queen Mary Hospital currently single cardiac centre worldwide vast experience use COMBO stent percutaneous coronary intervention , together intracoronary OCT profile stent 's healing progress subsequent neo-intimal growth behaviour . This current study protocol serve extension study evaluate long term clinical safety efficacy COMBO stent beyond 36 month post-implantation . This single centre observational study ass safety effectiveness clinical endpoint COMBO TM stent beyond 36 month . Clinical note subject previously participate EGO-COMBO Pilot Study ( UW 10-342 ) review clinical end point accord definition Academic Research Consortium angina symptom classify Canadian Cardiovascular Society Angina Classification .</detailed_description>
	<mesh_term>Coronary Restenosis</mesh_term>
	<criteria>Patient previously participate EGOCOMBO Pilot Study ( UW 10342 ) Patient previously participate EGOCOMBO Pilot Study ( UW 10342 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Safety efficacy</keyword>
	<keyword>Combo stent</keyword>
	<keyword>Late loss thrombosis</keyword>
	<keyword>Late loss catch</keyword>
</DOC>